Johnson and Johnson Submits FDA Request for Pediatric Tremfya Approval

Johnson & Johnson announced has submitted two supplemental biologics license applications (sBLAs) to the FDA for Tremfya (guselkumab) to be used in children aged 6 and older with moderate-to-severe plaque psoriasis (PsO) and children aged 5 and older with active juvenile psoriatic arthritis (jPsA).